CE Mark for Varipulse Platform for the treatment of symptomatic drug refractory recurrent paroxysmal atrial fibrillation – Biosense Webster (J&J)
Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech, announced European CE mark approval of the Varipulse Platform for the… read more.